Matthew J. Jackson, PhD, is a Research Fellow at the Center for Integration of Science and Industry at Bentley University. He received a BSc in Pharmacology from the University of Dundee and an MSc in Stratified Medicine and Pharmacological Innovation from the University of Glasgow. He gained his PhD in Cellular Medicine from Newcastle University, UK, investigating effects of oxidative damage on cellular bioenergetics in the ageing skin and worked with Hexis Labs Ltd and Newcastle University in a Knowledge Transfer Partnership associate role. At Bentley, his research interests focus on trends in new drug discovery including funding of R&D and societal impact of pharmaceutical activity. In addition to his current research, he also holds an adjunct professor role at Bentley University, teaching Human Biology within the department of Natural and Applied Sciences.
Matthew Jackson
By this expert
US Tax Dollars Funded Every New Pharmaceutical in the Last Decade
Amid debates over costs—and profits—from a coronavirus vaccine, a new study shows that taxpayers have been footing the bill for every new drug approved between 2010 and 2019
Government as the First Investor in Biopharmaceutical Innovation: Evidence From New Drug Approvals 2010鈥�2019
Amid debates over costs—and profits—from a coronavirus vaccine, a new study shows that taxpayers have been footing the bill for every new drug approved between 2010 and 2019
Big Pharma Wants to Pocket the Profits From a COVID Treatment You Already Paid For
Gilead鈥檚 shareholders want exorbitant profits from Remdesivir, even though it was the public that enabled its development.
Taxpayer Investment Leads New Drug Discoveries
New research points to critical role of public funding in drug discoveries and development for the last decade
Featuring this expert
Ledley, Cleary & Jackson鈥檚 INET working paper is cited in Missoulian
鈥淏ut COVID vaccines are by no means unique — most medicines developed and approved in the United States involve taxpayer investment. Between 2010 and 2019, every single new medicine approved by the Food and Drug Administration included taxpayer-funded research through NIH. Drug companies patent the drugs we pay to develop and then charge us exorbitant prices for them that increase every year — sometimes twice a year.鈥� — Terry Minow, Missoulian
Senator Baldwin cites INET's working paper on pharmaceutical funding in the HELP Committee meeting
鈥淔rom 2010 to 2019 the FDA approved 356 drugs. Recent research from Bentley University finds that NIH funding contributed to every single new drug approved. At a cost to the tax payer of roughly $230 billion dollars. In spite of this contribution the NIH is listed on only 27 of those patents. This suggests that while tax payers provide funding for the bulk of the early stage research they do not get patent protections supposedly secured by the by dole act. In essence American tax payers are paying the highest prices in the world for drugs they already paid to help develop.鈥� — Senator Tammy Baldwin
INET working paper is cited in a corrective letter to the editor of the Washington Post
“Her omission understates drug spending by almost one-third, or about $145 billion. She claimed most drugs are developed in pharmaceutical firms, but funding from the National 八卦爆料s of Health contributed to all 356 new drugs approved by the Food and Drug Administration from 2010 to 2019. Drug corporations take a handoff after the most risky research is done and a drug shows promise.” — David Mitchell
INET working paper on NIH's funding of new pharmaceuticals is cited
鈥淭hird, U.S. taxpayers foot a huge portion of the bill for basic science leading to new drugs. The National 八卦爆料s of Health is the single largest source of biomedical research in the world. In fact, NIH funding contributed to research associated with every single new drug approved by the FDA from 2010-2019, totaling $230 billion according to a recent report.鈥�